Cidara Therapeutics, Inc. (CDTX)

Insider Trading Filed: 2026-01-09

Key Insights

RA Capital Management, L.P. and its affiliates hold a significant 10% ownership stake in Cidara Therapeutics, Inc. (CDTX) through direct and indirect holdings.
The reported transactions show RA Capital exercising pre-funded warrants and disposing of common stock and preferred shares, likely as part of the announced merger with Merck.
The merger agreement provides for the acquisition of Cidara Therapeutics by Merck at a price of $221.50 per common share and $15,505 per preferred share, representing a substantial premium for investors.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC at a price of $221.50 per common share, representing a significant premium for shareholders.
The reporting person, Daniel D. Burgess, disposed of 150 common shares as part of the acquisition, indicating a change in his beneficial ownership of the company.
The acquisition resulted in the cancellation and conversion of all outstanding stock options held by the reporting person into the right to receive cash payments based on the merger consideration.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics was acquired by Merck in a $221.50 per share deal, representing a significant premium for shareholders.
The reporting person, Joshua Resnick, is a director at Cidara and held stock options that became fully vested and were cashed out in the acquisition.
The reporting person's stock options were actually held for the benefit of RA Capital Management, L.P., with the reporting person disclaiming beneficial ownership.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. has been acquired by Merck Sharp & Dohme LLC, with Merck completing a tender offer to acquire all outstanding shares of Cidara at $221.50 per share.
As a result of the acquisition, all outstanding stock options held by the reporting person, Ryan Spencer, have been cancelled and converted into the right to receive cash payments based on the excess of the acquisition price over the exercise price of the options.
This transaction represents a significant liquidity event for the company's shareholders and insiders, including the reporting person, who is a director of Cidara Therapeutics.

Insider Trading Filed: 2026-01-07

Key Insights

The filing indicates that Cidara Therapeutics, Inc. (CDTX) was acquired by Merck through a tender offer and merger, resulting in the cancellation and cash-out of all outstanding stock options held by the reporting person, James Merson.
The transaction price of $221.50 per common share represents a significant premium over the exercise prices of the cancelled options, suggesting the deal was favorable for Cidara shareholders.
The full vesting and cash-out of the options suggests that the reporting person, a director of Cidara, likely benefited financially from the acquisition.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. (CDTX) has been acquired by Merck Sharp & Dohme LLC in a merger transaction completed on January 7, 2026.
The reporting person, Carin Canale-Theakston, held various stock options in Cidara Therapeutics which have been cancelled and converted into cash payments as part of the merger agreement.
The merger agreement provides for the acquisition of all outstanding shares of Cidara Therapeutics at $221.50 per common share, representing a significant premium for shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. (CDTX) has been acquired by Merck in a merger transaction, with shareholders receiving $221.50 per common share and $15,505 per preferred share.
The merger agreement was signed in November 2025, and the transaction was completed on January 7, 2026, with Cidara becoming a wholly-owned subsidiary of Merck.
All outstanding stock options held by Cidara employees and directors have been cancelled and converted into the right to receive cash payments based on the merger consideration and the exercise prices of the options.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. was acquired by Merck through a tender offer and merger, resulting in the disposition of all outstanding common and preferred shares.
The reporting person, Chrysa Mineo, had various stock options that became fully vested and were cancelled in the merger, with the holder receiving cash consideration.
The transaction price of $221.50 per common share represents a significant premium for Cidara Therapeutics shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. (CDTX) was acquired by Merck Sharp & Dohme LLC, with the tender offer completed on January 7, 2026.
All outstanding stock options held by the reporting person, Theodore R. Schroeder, were cancelled and converted into the right to receive cash consideration of $221.50 per share, less the exercise price.
The transaction resulted in the complete exit of the reporting person's equity ownership position in Cidara Therapeutics.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC in a cash transaction at $221.50 per common share, representing a premium for shareholders.
All of the reporting person's common stock and employee stock options were disposed of as part of the acquisition, indicating a complete exit by the CEO.
The transaction was executed through a tender offer and subsequent merger, providing liquidity for Cidara's shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. (CDTX) is being acquired by Merck Sharp & Dohme LLC in a cash transaction at $221.50 per common share.
The Chief Financial Officer of Cidara Therapeutics, Frank Karbe, has disposed of all his common stock holdings in the company as part of the acquisition.
Karbe's outstanding stock options have also been cancelled and converted into the right to receive cash based on the acquisition price.

Insider Trading Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. (CDTX) was acquired by Merck in a $221.50 per share tender offer, resulting in the cancellation and cash-out of all outstanding common and preferred stock.
The reporting person, Shane Ward, held various employee stock options which were canceled and converted into the right to receive cash payments based on the merger consideration.
The transaction represents a significant liquidity event for Cidara Therapeutics shareholders, as the $221.50 per share cash consideration represents a substantial premium over the company's prior trading price.

Insider Trading Filed: 2026-01-07

Key Insights

The filing indicates that Cidara Therapeutics, Inc. (CDTX) was acquired by Merck Sharp & Dohme LLC in a merger transaction on January 7, 2026, where common shareholders received $221.50 per share in cash.
As a result of the merger, the reporting person, Nicole Negar Davarpanah, the Chief Medical Officer of Cidara, disposed of all her common shares and outstanding stock options.
The transaction represents a significant event for Cidara shareholders, as they received a substantial premium over the previous market price for their shares.

Insider Trading Filed: 2026-01-07

Key Insights

The filing reveals significant insider buying activity by the President and CEO of Cidara Therapeutics, Inc. over the past 5 years, indicating management's confidence in the company's prospects.
The report shows the CEO has consistently increased his indirect beneficial ownership of the company's stock, primarily through purchases made by a trust, suggesting long-term alignment with shareholders.
The filing corrects several errors in previous Form 4 filings, demonstrating the company's commitment to providing accurate and transparent reporting of insider transactions.

Current Report Filed: 2026-01-07

Key Insights

Cidara Therapeutics, Inc. has been acquired by Merck Sharp & Dohme LLC through a tender offer and subsequent merger, resulting in Cidara becoming a wholly-owned subsidiary of Merck.
The acquisition was completed on January 7, 2026, after Merck's subsidiary acquired approximately 88.3% of Cidara's outstanding shares through the tender offer.
As part of the acquisition, Cidara has terminated its various equity incentive plans, including the 2015 Equity Incentive Plan, the 2020 Inducement Incentive Plan, the 2024 Equity Incentive Plan, and the 2015 Employee Stock Purchase Plan.

Insider Trading Filed: 2025-12-29

Key Insights

The reporting person, Jeffrey Stein, who is the President and CEO of Cidara Therapeutics, Inc. (CDTX), has been engaging in significant insider trading activity, including multiple gift transfers of the company's shares to a trust and a donor-advised fund.
The transactions indicate that the reporting person is actively managing his equity holdings in the company, potentially as part of a broader portfolio strategy or for charitable purposes.
The timing and volume of the transactions may be of interest to investors as they could provide insights into the reporting person's outlook on the company's future prospects.

Insider Trading Filed: 2025-12-29

Key Insights

The reporting person, Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, Inc., has made a bona fide gift of 450 shares of the issuer's common stock to a donor-advised fund for charitable purposes, indicating a philanthropic gesture.
The reporting person continues to hold 20,886 shares of the issuer's common stock, representing her direct ownership in the company following the reported transaction.
The reporting person acquired an additional 50 shares of the issuer's common stock through the company's Employee Stock Purchase Plan on December 18, 2025, demonstrating her ongoing participation in the company's equity programs.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information